AntiTum Cancer Research Results

AntiTum, AntiTumor: Click to Expand ⟱
Source:
Type:
AntiTumor


BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
4364- AgNPs,    Selective cytotoxicity of green synthesized silver nanoparticles against the MCF-7 tumor cell line and their enhanced antioxidant and antimicrobial properties
- in-vitro, BC, MCF7
TumCD↑, selectivity↑, *antiOx↑, *Inflam↓, AntiTum↑, ROS↑,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
5169- Ash,    The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin
- in-vitro, BC, MCF7
AntiTum↑, angioG↓, Vim↓,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4818- ASTX,  MEL,    Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
TumCD↑, DNAdam↑, *antiOx↑, *AntiTum↑, Inflam↓, tumCV↓, Bcl-2↓, Apoptosis↓, selectivity↑, eff↑, Dose↓,
2024- Bos,    Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10
MMP↓, Cyt‑c↑, ROS↑, Casp8↑, Casp9↑, AntiTum↑, selectivity↑, TumCCA↑,
5702- BRU,  BJ,    Brusatol inhibits metastasis of triple-negative breast cancer through metabolic reprogramming
- in-vitro, BC, NA
AntiTum↑, PPP↓, Glycolysis↓, TCA↓, NADPH↓, ROS↑, chemoP↑, e-LDH↑, TumMeta↓, Glycolysis↓,
6006- CGA,    Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF-κB signaling pathway
- in-vitro, BC, NA
NF-kB↓, AntiTum↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓,
6030- CGA,    Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NF‑κB signaling pathway
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-453 - in-vitro, Nor, MCF10
NF-kB↓, AntiTum↑, tumCV↓, TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, TumCG↓, OS↑, TumMeta↓, CD4+↑, CD8+↑, Imm↑,
1112- FA,    Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, NA
tumCV↓, Apoptosis↑, AntiTum↑, TumMeta↓, EMT↓, TumVol↓, TumW↓,
7029- GA,    Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, Nor, MCF10
AntiTum↑, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cycE/CCNE↓, CDK2↓, P21↑, p27/CDKN1B↑, Casp9↑, Casp3↑, ROS↑, mtDam↑, i-Ca+2↑, *ROS↓, *Apoptosis↓, TumCG↓,
1969- GamB,    Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
AntiTum↑, TumCI↓, Apoptosis↑, ROS↑, Cyt‑c↑, Akt↓, mTOR↓, TumCG↓, TumMeta↓,
7568- HYP,  PacT,    Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling
- in-vitro, BC, MDA-MB-231
Inflam↓, AntiTum↑, selectivity↑, chemoP↑, TumCI↓, ChemoSen↑, tumCV↓, Apoptosis↑, Casp3↑, TLR4↓, NF-kB↓,
7674- iod,    Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway
- in-vitro, BC, NA
AntiTum↑, selectivity↑, MMP↓, antiOx↑, Thiols↓, Bcl-2↓, BAX↑, eff↓, Casp↑, ROS↓, ROS↑, Cyt‑c↑, AIF↑,
7679- iod,    Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin
- in-vivo, BC, MCF7
AntiTum↑, tumCV↓, Apoptosis↑, Bax:Bcl2↑, Bcl-2↓, MDR1↑, PPARγ↑, CD44↓,
8049- IVM,    Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
- vitro+vivo, BC, NA
*AntiP↑, AntiCan↑, AntiTum↑, PAK1↓, p‑Akt↓, Akt↓, mTOR↓, TumCG↓,
8243- LCA,    Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer
- in-vitro, BC, MDA-MB-231
Inflam↓, AntiTum↑, TumAuto↑, Sp1/3/4↓, TumCMig↓, MAPK↓, Akt↓, cl‑Casp3↑, cl‑Casp9↑, Bcl-2↓, Cyt‑c↑, TumCP↓, ROS↑, Apoptosis↑, TumCMig↓, TumCI↓, MMP↓, γH2AX↑,
5604- NaHCO3,    Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
- vitro+vivo, Melanoma, B16-BL6 - in-vitro, BC, 4T1
eff↑, eff↑, TumMeta↓, pH↑, CaMKII ↑, CREB↑, PGC-1α↑, AntiTum↑, Imm↑, CD8+↑, TAMS↑,
1797- NarG,    Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway
- in-vitro, BC, MDA-MB-231
TumCG↓, β-catenin/ZEB1↓, AntiTum↑, Apoptosis↑, TumCCA↑, P21↑, survivin↓,
6488- Nimb,    Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation
- in-vitro, BC, NA
TumCP↓, AntiTum↑, TumMeta↓, selectivity↑,
7431- Poly,    Garlic peel extract as an antioxidant inhibits triple‐negative breast tumor growth and angiogenesis by inhibiting cyclooxygenase‐2 expression
- vitro+vivo, BC, 4T1
other↝, AntiTum↑, Dose↝, TumCG↓, ALAT↓, AST↓, hepatoP↑, COX2/PTGS2↓, MMP2↓, MMP9↓,
871- RES,  CUR,  QC,    The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
T-Cell↑, Neut↓, Macrophages↓, ROS↑, MMP↓, other↓, AntiTum↑, TumVol↓,
4896- Sper,  immuno,    Spermidine potentiates anti-tumor immune responses and immunotherapy sensitivity in breast cancer
- vitro+vivo, BC, NA
eff↑, AntiTum↑,
6174- TM,    Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse
- Trial, BC, NA
OS↑, toxicity↓, AntiTum↑, Copper↓, angioG↓,

Showing Research Papers: 1 to 24 of 24

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Copper↓, 1,   NRF2↓, 1,   ROS↓, 1,   ROS↑, 9,   Thiols↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MMP↓, 4,   MMP↑, 1,   mtDam↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   CREB↑, 1,   Glycolysis↓, 2,   e-LDH↑, 1,   NADPH↓, 1,   PPARγ↑, 1,   PPP↓, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   p‑Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 10,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   Cyt‑c↑, 4,   MAPK↓, 1,   p27/CDKN1B↑, 1,   survivin↓, 1,   TumCD↑, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↑, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 1,   tumCV↓, 6,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 3,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   EMT↓, 3,   mTOR↓, 2,   PI3K↓, 1,   p‑PI3K↓, 1,   TumCG↓, 6,  

Migration(tgid=13) ⓘ

i-Ca+2↑, 1,   MMP2↓, 1,   MMP9↓, 1,   PAK1↓, 1,   TumCI↓, 6,   TumCMig↓, 5,   TumCP↓, 4,   TumMeta↓, 6,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   TAMS↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 1,   Imm↑, 2,   Inflam↓, 3,   Macrophages↓, 1,   Neut↓, 1,   NF-kB↓, 3,   T-Cell↑, 1,   TLR4↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↓, 1,   Dose↝, 2,   eff↓, 1,   eff↑, 4,   MDR1↑, 1,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   e-LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 23,   chemoP↑, 2,   hepatoP↑, 1,   OS↑, 3,   toxicity↓, 1,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 2,  
Total Targets: 99

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiP↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   ROS↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: AntiTum, AntiTumor
2 Astaxanthin
2 Chlorogenic acid
2 iodine
1 Silver-NanoParticles
1 Apigenin (mainly Parsley)
1 Ashwagandha(Withaferin A)
1 Melatonin
1 Boswellia (frankincense)
1 brusatol
1 Brucea javanica
1 Ferulic acid
1 Gallic acid
1 Gambogic Acid
1 Hyperoside
1 Paclitaxel/Taxol
1 Ivermectin
1 Licochalcone A
1 Bicarbonate(Sodium)
1 Naringin
1 Nimbolide
1 Polyphenols
1 Resveratrol
1 Curcumin
1 Quercetin
1 Spermidine
1 immunotherapy
1 tetrathiomolybdate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:913  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page